江陆斌

江陆斌

2024-09-11来源：中国科学院天然免疫与慢性疾病重点实验室



个人简介

江陆斌，研究员、课题组长，免疫应答与免疫治疗全国重点实验室课题组负责人。本科和硕士毕业于南昌大学，博士毕业于中国科学院上海植物生理生态研究所。随后赴美国国立卫生研究院（NIH），先后就职博士后及研究助理，从事疟疾疫苗的研发工作。2012年起在研究所建立了疟原虫表观遗传学实验室，致力于疟原虫表观遗传学研究，并在此基础上探索疟疾防控的新策略。已发表SCI研究论文40余篇，其中以通讯作者在Nature（2篇）、PNAS（4篇）、Nucleic Acids Research（1篇）等国际期刊发表研究论文多篇。申请抗疟药国家发明专利和国际专利PCT共6项，其中一种小分子候选药物已进入临床前研究。


研究方向

以原创的表观遗传基因编辑技术为手段，研究疟疾发病过程中介导疟原虫免疫逃逸和多通路感染的表观遗传调控机制，挖掘疟疾疫苗和抗疟药研发的新靶点，探索疟疾防控的新策略。



科研成果情况

    1. Li R, Ling D, Tang T, Huang Z, Wang M, Ding Y, Liu T, Wei H, Xu W, Mao F, Zhu J, Li X*, Jiang L*, Li J*. Discovery of Novel Plasmodium falciparum HDAC1 Inhibitors with Dual-Stage Antimalarial Potency and Improved Safety Based on the Clinical Anticancer Drug Candidate Quisinostat. J. Med. Chem. 2021 Feb 25;64(4):2254-2271. 

    2. Huang Z#, Li R#, Tang T#, Ling D#, Wang M#, Xu D, Maoxin Sun, Zheng L, Zhu F, Min H, Boonhok R, Ding Y, Wen Y, Chen Y, Li X, Chen Y, Liu T, Han J, Miao J, Fang Q, Cao Y, Tang Y, Cui J, Xu W, Cui L, Zhu J, Wong G, Li J, Jiang L*. A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1. Cell Discovery. 2020 Dec 11;6(1):93. 

    3. Zhou J, Huang Z, Zheng L, Hei Z, Wang Z, Yu B, Jiang L*, Wang J*, Fang P*. Inhibition of Plasmodium falciparum Lysyl-tRNA synthetase via an anaplastic lymphoma kinase inhibitor. Nucleic Acids Res. 2020 Nov 18;48(20):11566-11576. 

    4. Liang X#, Jiang Z#, Huang Z#, Li F#, Chen C, Hu C, Wang W, Hu Z, Liu Q, Wang B, Wang L, Qi Z, Liu J*, Jiang L*, Liu Q*. Discovery of 6'-chloro-N-methyl-5'- (phenylsulfonamido)-[3,3'-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium. Eur J Med Chem. 2020;188:112012. 

    5. Yin S#*, Fan Y#, He X, Wei G, Wen Y, Zhao Y, Shi M, Wei J, Chen H, Han J, Jiang L*, Zhang Q*. The cryptic unstable transcripts are associated with developmentally regulated gene expression in blood-stage Plasmodium falciparum. RNA Biol. 2020:1-15. 

    6. Yuan J#, Chang SY#, Yin SG#, Liu ZY#, Cheng X#, Liu XJ, Jiang Q, Gao G, Lin DY, Kang XL, Ye SW, Chen Z, Yin JA, Hao P, Jiang L*, Cai SQ*. Two conserved epigenetic regulators prevent healthy ageing. Nature. 2020;579(7797):118-22. 

    7. Xiao B#, Yin S, Hu Y, Sun M, Wei J, Huang Z, Wen Y, Dai X, Chen H, Mu J, Cui L, Jiang L*. Epigenetic editing by CRISPR/dCas9 in Plasmodium falciparum. Proc Natl Acad Sci U S A. 2019;116(1):255-60. 

    8. Li Z#, Yin S#, Sun M#, Cheng X#, Wei J, Gilbert N, Miao J, Cui L, Huang Z*, Dai X*, Jiang L*. DNA helicase RecQ1 regulates mutually exclusive expression of virulence genes in Plasmodium falciparum via heterochromatin alteration. Proc Natl Acad Sci U S A. 2019;116(8):3177-82.  

    9. Chen W#, Yao X#, Huang Z#, Mao F, Guan L, Tang Y, Jiang H, Li J, Huang J*, Jiang L*, Zhu J*. Novel dual inhibitors against FP-2 and PfDHFR as potential antimalarial agents: Design, synthesis and biological evaluation. Chinese Chemical Letters. 2019;30(01):270-4. 

    10. Jing Q#, Cao L#, Zhang L#, Cheng X, Gilbert N, Dai X, Sun M, Liang S*, Jiang, L*. (2018). Plasmodium falciparum var Gene Is Activated by Its Antisense Long Noncoding RNA. Frontiers in Microbiology, 2018, 9: 3117. 

    11. Chen W#, Huang Z#, Wang W#, Mao F, Guan L, Tang Y, Jiang H, Li J, Huang J*, Jiang L*, Zhu J*. Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembly. Bioorg Med Chem. 2017;25(24):6467-78. 

    12. Yang Y #, Yu Y#, Li X#, Li J, Wu Y, Yu J, Ge J, Huang Z, Jiang L*, Rao Y*, Yang M*. Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule to Eliminate Drug-Resistant Malaria. J Med Chem. 2017, 60(5), 1994–2005.  

    13. Liu P*, Jiang L*. Conditional knockout tools: Application of site-specific incorporation of unnatural amino acid via genetic code expansion in viral and parasite vaccine development. Synth Syst Biotechnol. 2017 Mar 11;2(1):2-4. 

    14. Shigang Yin, Xiu Cheng, Xu Zhang, Jiang L*. Epigenetic regulations in immune evasion of the deadliest malaria parasite Plasmodium falciparum. Science Foundation in China. 22 (1), 43-56(2014). 

    15. Jiang L*, Mu J, Zhang Q, Ni T, Srinivasan P, Rayavara K, Yang W, Turner L, Lavstsen T, Theander TG, Peng W, Wei G, Jing Q, Wakabayashi Y, Bansal A, Luo Y, Ribeiro J MC, Scherf A, Aravind L, Zhu J, Zhao K & Miller LH*. PfSET2vs methylation of histone H3K36 represses virulence genes in Plasmodium falciparum. Nature. 499, 223-227 (2013) . 

    16. Jiang L*, Gaur D, Mu J, Zhou H, Long CA & Miller LH*. Evidence for erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria vaccine. Proc Natl Acad Sci U S A. 108, 7553-7358 (2011). 

    17. Jiang L*, López-Barragán MJ, Jiang H, Mu J, Gaur D, Zhao K, Felsenfeld G & Miller LH*. Epigenetic control of the variable expression of a Plasmodium falciparum receptor protein for erythrocyte invasion. Proc Natl Acad Sci U S A. 107, 2224-2229 (2010).  

    18. 张旭，江陆斌*。恶性疟原虫免疫逃避的表观遗传调控。中国科学基金，2014年第二期，35-36页.（特邀综述）。 

    19. 景庆庆, 程秀, 江陆斌*。探秘恶性疟原虫免疫逃逸的表观遗传调控机制。中国细胞生物学学报, 35(9): 1255–1258, 2013（特邀综述）。 

    专利： 

    1. Quisinostat,一种新型的高效抗疟药物，江陆斌、黄正辉，中国专利申请号：CN201610096388.9, 申请日期：2016-02-22。 

    2. 含Trapoxin A和阿莫地喹的药物组合物及其应用, 江陆斌、王琪、黄正辉，中国专利申请号：CN201610174070.8，申请日期：2016-03-24。 

    3. 2,8-二氮杂-螺-[4,5]-癸烷类嘧啶-异羟肟酸化合物及其用途，李剑、江陆斌、李若曦、汤同柯、黄正辉、凌大正、王熳炯、朱进，中国专利申请号：CN201910214972.3，申请日期：2019-03-20。 

    4. 环状或螺环二胺类嘧啶-异羟肟酸及其用途，李剑、江陆斌、李若曦、黄正辉、汤同柯、凌大正、王熳炯、朱进，中国专利申请号：CN201910212087.1，申请日期：2019-03-20。 

    5. Quisinostat，一种新型的高效抗疟药物，江陆斌、黄正辉，专利申请号：PCT/CN2017/074255，申请日期：2017-02-21。 

    6. 2,7-二氮杂-螺[4.4]壬烷类异羟肟酸嘧啶类化合物及其制备和应用，李剑、江陆斌、凌大正、黄正辉、王熳炯、李若曦、汤同柯、朱进，专利申请号：PCT/CN2019/077357，申请日期：2019-03-07。




上一篇：下一篇：